Johnson & Johnson reported solid third-quarter results with adjusted earnings surpassing expectations and provided positive guidance for the full year. Despite some challenges in U.S. sales and increased costs, the strong performance in international markets and strategic initiatives likely bolster investor confidence in the short term.

[1]